• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Screening of PECAM antagonist having anti-tumor angiogenesis

Research Project

Project/Area Number 16K08601
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field General medical chemistry
Research InstitutionInstitute of Physical and Chemical Research

Principal Investigator

Kitazume Shinobu  国立研究開発法人理化学研究所, 脳神経科学研究センター, 客員研究員 (80301753)

Project Period (FY) 2016-04-01 – 2019-03-31
Project Status Completed (Fiscal Year 2018)
Budget Amount *help
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywords腫瘍血管新生 / シアル酸 / PECAM / インテグリン / VEGFR2 / アポトーシス / α2,6-シアル酸 / ST6Gal I / 血管内皮細胞 / 糖鎖 / VEGFR2 / 化合物アレイ / 血管内内皮細胞 / 血管新生 / アンタゴニスト
Outline of Final Research Achievements

We found that ST6Gal I KO mice, which lack a2,6-sialic acid, exhibit retarded tumor growth due to impaired tumor angiogenesis. Actualy ST6Gal I KO endothelial cells exhibited a reduction in the cell surface residency of platelet endothelial cell adhesion molecule (PECAM). In this study, we found that in ST6Gal I KO cells, cell surface PECAM-VEGFR2 complexes were lost, and both VEGFR2 internalization and the VEGFR-dependent signaling pathway were enhanced. Second, enhanced anoikis was observed, suggesting that theabsence of α2,6-sialic acid leads to dysregulated integrin signaling. Taken together, acid, leading to abnormal signal transduction, resulting in enhanced endothelial apoptosis. Endothelial α2,6-sialylation could be a novel target for antiangiogenesis
therapy.

Academic Significance and Societal Importance of the Research Achievements

血管内皮細胞におけるα2,6-シアル酸は、新規の抗血管新生阻害剤標的となり得ることが本研究から明らかになりました。α2,6-シアル酸欠損マウスは免疫系の軽微な異常が見られるため、阻害剤は免疫系の副作用をもたらす可能性があります。現在、α2,6-シアル酸を模倣した低分子化合物のスクリーニング中であり、将来的にPECAMの相互的結合を阻害するような選択的化合物を得られれば、新たな抗血管新生阻害剤の候補になると期待できます。

Report

(4 results)
  • 2018 Annual Research Report   Final Research Report ( PDF )
  • 2017 Research-status Report
  • 2016 Research-status Report
  • Research Products

    (18 results)

All 2018 2017 2016 Other

All Journal Article (8 results) (of which Int'l Joint Research: 2 results,  Peer Reviewed: 7 results,  Open Access: 6 results) Presentation (5 results) (of which Int'l Joint Research: 4 results,  Invited: 3 results) Book (1 results) Remarks (2 results) Patent(Industrial Property Rights) (2 results)

  • [Journal Article] Glycosylation controls cooperative PECAM-VEGFR2-β3 integrin functions at the endothelial surface for tumor angiogenesis.2018

    • Author(s)
      1.Imamaki R. Ogawa K, Kizuka Y, Komi Y, Kojima S, Kotani N, Honke K, Honda T, Taniguchi N, and Kitazume S*.
    • Journal Title

      Oncogene

      Volume: 37 Pages: 4287-4299

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] CD22-binding synthetic sialosides regulate B lymphocyte proliferation through CD22 ligand-dependent and independent pathways, and enhances antibody production in mice2018

    • Author(s)
      2.Matsubara N, Imamura A, Yonemiz Tu, Akatsu C, Yang H, Ueki A, Watanabe N, Abdu-Allah H, Numoto N, Takematsu H, Kitazume S, Tedder FT, Marth JD, Ito N, Ando H, Ishida H, Kiso M, and Tsubata T
    • Journal Title

      Frontiers in Immunology

      Volume: - Pages: 820-820

    • DOI

      10.3389/fimmu.2018.00820

    • Related Report
      2018 Annual Research Report 2017 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] High affinity sugar ligands of C-type lectin receptor langerin.2018

    • Author(s)
      Ota F, Hirayama T, Kizuka Y, Yamaguchi Y, Fujinawa R, Nagata M; Ismanto HS, Lepenies, Aretz J, Rademacher C, Seeberger PH; Angata T, Kitazume S, Yoshida K, Betsuyaku T, Kida K Yamasaki S, and Taniguchi N
    • Journal Title

      BBA - General Subjects

      Volume: - Issue: 7 Pages: 1592-1601

    • DOI

      10.1016/j.bbagen.2018.04.004

    • Related Report
      2018 Annual Research Report 2017 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] 1.Imamaki R. Ogawa K, Kizuka Y, Komi Y, Kojima S, Kotani N, Honke K, Honda T, Taniguchi N, and Kitazume S2018

    • Author(s)
      1.Imamaki R. Ogawa K, Kizuka Y, Komi Y, Kojima S, Kotani N, Honke K, Honda T, Taniguchi N, and Kitazume S
    • Journal Title

      Oncogene

      Volume: - Issue: 31 Pages: 4287-4299

    • DOI

      10.1038/s41388-018-0271-7

    • Related Report
      2017 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Core fucose is critical for CD14-dependent Toll-like receptor 4 signaling2017

    • Author(s)
      4.Iijima J, Kobayashi S, Kitazume S*, Kizuka Y, Fujinawa R, Korekane H, Shibata T, Saitoh S, Akashi-Takamura S, Miyake K, Miyoshi E, and Taniguch N
    • Journal Title

      Glycobiology

      Volume: 2017 Issue: 11 Pages: 1006-1015

    • DOI

      10.1093/glycob/cwx075

    • Related Report
      2017 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Inhibitory Role of α2,6-Sialylation in Adipogenesis.2017

    • Author(s)
      Kaburagi T, Kizuka Y, Kitazume S, and Taniguchi N.
    • Journal Title

      J. Biol. Chem

      Volume: -

    • Related Report
      2016 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] PECAM2017

    • Author(s)
      Kitazume S
    • Journal Title

      Encyclopedia in Signaling Molecules

      Volume: -

    • Related Report
      2016 Research-status Report
  • [Journal Article] Reactivity of anti-HNK-1 antibodies to branched O-mannose glycans associated with demyelination.2017

    • Author(s)
      Sakuda K, Kizuka Y, Yamaguchi Y, Tanaka K, Ogiwara K, Segawa T, Hagiwara Y, Matsuo I, Ogawa H, Taniguchi N, and Kitazume S
    • Journal Title

      BBRC

      Volume: 487 Pages: 450-456

    • Related Report
      2016 Research-status Report
    • Peer Reviewed
  • [Presentation] Endothelial O-GalNAc glycosylation pathway determines APP processing for vascular Aβ deposition2017

    • Author(s)
      Kitazume S
    • Organizer
      AD/PD2016
    • Place of Presentation
      ウイーン(オーストリア)
    • Year and Date
      2017-03-30
    • Related Report
      2016 Research-status Report
    • Int'l Joint Research
  • [Presentation] Endothelial glycan is an attractive therapeutic target2017

    • Author(s)
      Kitazume S
    • Organizer
      RIKEN International symposium Systems Glycobiology and Beyond
    • Related Report
      2017 Research-status Report
    • Int'l Joint Research / Invited
  • [Presentation] How glycosylation affects amyloid beta production?2017

    • Author(s)
      Kitazume S
    • Organizer
      Glyconeuro 1st
    • Related Report
      2017 Research-status Report
    • Int'l Joint Research / Invited
  • [Presentation] アルツハイマー病態をコントロールする糖鎖修飾2017

    • Author(s)
      爪しのぶ
    • Organizer
      ConBio2017
    • Related Report
      2017 Research-status Report
    • Invited
  • [Presentation] アミロイド産生と脳アミロイド アンギオパチーを規定する 血管内皮細胞のO-GalNAc型糖鎖2016

    • Author(s)
      北爪しのぶ
    • Organizer
      第35回日本糖質学会
    • Place of Presentation
      高知市文化プラザ(高知県・高知市)
    • Related Report
      2016 Research-status Report
    • Int'l Joint Research
  • [Book] 生体の科学2016

    • Author(s)
      北爪しのぶ
    • Total Pages
      11
    • Publisher
      医学書院
    • Related Report
      2016 Research-status Report
  • [Remarks]

    • URL

      http://www.fmu.ac.jp/univ/kenkyuseika/research/180510.html

    • Related Report
      2017 Research-status Report
  • [Remarks]

    • URL

      http://www.riken.jp/pr/press/2018/20180510_1/

    • Related Report
      2017 Research-status Report
  • [Patent(Industrial Property Rights)] 多発性硬化症マーカー2018

    • Inventor(s)
      北爪しのぶ、作田香子、谷口直之、橋本康弘、本多たかし、斎藤清
    • Industrial Property Rights Holder
      北爪しのぶ、作田香子、谷口直之、橋本康弘、本多たかし、斎藤清
    • Industrial Property Rights Type
      特許
    • Industrial Property Number
      2018-028329
    • Filing Date
      2018
    • Related Report
      2017 Research-status Report
  • [Patent(Industrial Property Rights)] 認知症診断の為の可溶型アミロイドβ前駆体タンパク質770β切断産物の検出方法2016

    • Inventor(s)
      北爪しのぶ、谷口直之、立田由里子、西道隆臣、橋本康弘、本多たかし
    • Industrial Property Rights Holder
      北爪しのぶ、谷口直之、立田由里子、西道隆臣、橋本康弘、本多たかし
    • Industrial Property Rights Type
      特許
    • Filing Date
      2016-04-22
    • Acquisition Date
      2017-01-22
    • Related Report
      2016 Research-status Report

URL: 

Published: 2016-04-21   Modified: 2020-03-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi